Clinical Trial Update: BAX 855 PK-guided Dosing [Phase 3]

View source ↗

Summary

A Phase 3 trial update on PK-guided dosing for BAX 855 in Hemophilia A has completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• BAX 855

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Hemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2019-08-26